SBIR/STTR Research Award

Discovery of Small Molecule hACC2 Inhibitors for Treatment of Obesity

Award identifier d4c2495a0666da6e93fa9f9a97e1d5ce4e88e01b96c558f486214a369323e72aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Chemdiv, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
WZKETC8NCBF1
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism required for the addition of CO2 to acetyl-CoA to make malonyl-CoA. In mammals, malonyl-CoA serves as a precursor for the synthesis of fatty acids but it also regulates fatty acid oxidation in mitochondria. There are two ACC isozymes in humans, with very similar amino acid sequences, differing mainly by a 200-residue N-terminal extension on ACC2 that directs this form of the enzyme to mitochondria. There, ACC2-catalyzed synthesis of malonyl- CoA leads to suppression of fatty acid transport and subsequent oxidation. ACC1- synthesized malonyl-CoA is used for fatty acid synthesis. We propose to screen a small- molecule library to find novel inhibitors of ACC2 as lead compounds for the development of new pharmacotherapies to treat obesity. We have constructed yeast gene- replacement strains depending for growth on either human ACC. Our research has already shown that growth of such ACC gene-replacement strains is inhibited by compounds targeting foreign ACCs. We have developed and tested a high throughput protocol necessary to screen large chemical libraries. We also propose to conduct follow-up experiments to determine the specificity of any new inhibitor identified in the screen, using our collection of yeast gene-replacement strains carrying different ACCs, and to confirm ACC as their target, using enzymatic assays. Obesity is a common and prevalent nutritional disorder linked to significant morbidity and premature mortality caused by other serious medical conditions such as diabetes and coronary disease. Acetyl-CoA carboxylase, a key lipid metabolic enzyme, is being investigated as a potential target for new pharmacotherapies to treat the disorder. New medications based on small-molecule inhibitors of the enzyme acting by increasing fatty acid degradation by oxidation or decreasing fatty acid synthesis could become new urgently needed tools to combat the disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

4 SBIR/STTR records share this UEI (2004–2007). Reported award amounts total $1,050,086. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.